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Abstract
Background: Few patients with lung metastases from colorectal cancer (CRC) are candidates for surgical therapy with 
a curative intent, and it is currently impossible to identify those who may benefit the most from thoracotomy. The aim 
of this study was to determine the impact of various parameters on survival after pulmonary metastasectomy for CRC.
Methods: We performed a retrospective analysis of 40 consecutive patients (median age 63.5 [range 33-82] years) who 
underwent resection of pulmonary metastases from CRC in our institution from 1996 to 2009.
Results: Median follow-up was 33 (range 4-139) months. Twenty-four (60%) patients did not have previous liver 
metastases before undergoing lung surgery. Median disease-free interval between primary colorectal tumor and 
development of lung metastases was 32.5 months. 3- and 5-year overall survival after thoracotomy was 70.1% and 
43.4%, respectively. In multivariate analysis, the following parameters were correlated with tumor recurrence after 
thoracotomy; a history of previous liver metastases (HR = 3.8, 95%CI 1.4-9.8); and lung surgery other than wedge 
resection (HR = 3.0, 95%CI 1.1-7.8). Prior resection of liver metastases was also correlated with an increased risk of death 
(HR = 5.1, 95% CI 1.1-24.8, p = 0.04). Median survival after thoracotomy was 87 (range 34-139) months in the group of 
patients without liver metastases versus 40 (range 28-51) months in patients who had undergone prior hepatectomy 
(p = 0.09).
Conclusion: The main parameter associated with poor outcome after lung resection of CRC metastases is a history of 
liver metastases.
Background
Resection of hepatic metastases from colorectal cancer
(CRC) has yielded 5-year survival rates ranging from 25%
to 50% [1,2]. Similarly, resection of lung metastases from
CRC has yielded 5-year survival rates ranging from 20%
up to 60% in large series [3,4]. Based on these encourag-
ing results, many surgeons have expanded the indications
for resecting metastatic CRC, and there is nowadays
growing pressure to perform lung metastasectomy, even
in asymptomatic CRC patients. The issue therefore is to
select the patients with pulmonary metastases who are
good candidate for surgical therapy with a curative intent.
Unfortunately, it is currently not possible to do so - hence
the necessity for surgeons to preoperatively identify clin-
ico-pathological parameters predicting survival after tho-
racotomy.
LM develop in 5-15% of CRC patients according to two
different scenarios: the first scenario, most common, is
the metachronous development of lung metastases in a
patient who has previously developed in transit liver
metastases; in the second scenario - less frequent -
patients develop lung metastases synchronous or
metachronous to primary colorectal cancer, but without
evidence of liver metastases ("skip metastases") [5]. In the
latter situation, the reason why the liver does not provide
an adequate soil for the metastases to develop is unclear,
but might involve, among other factors, deficient tumor
angiogenesis [6]. Most CRC patients included in surgical
series of pulmonary metastasectomy belonged to the sec-
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come of CRC patients who underwent resection of lung
metastases with a curative intent. Reported 5-year overall
survival rates range from 24% [7] to 68% [8], indicating
that these studies reflect the experience of highly special-
ized centres with a selected subset of patients [9]. Various
factors associated with prolonged survival after surgery
for lung metastases from CRC have been identified,
including: a) a long disease-free interval (defined as the
time from colectomy to the development of lung metasta-
ses [10-12]; b) prethoracotomy carcinoembryogenic anti-
gen (CEA) level <5NG/ML [13-15]; c) a single isolated
metastasis < 3 cm in size [16-18]; and d) the absence of
thoracic lymph node invasion [19,20]. By contrast, a his-
tory of previous liver metastases has never been docu-
mented as statistically significant. However, many series
of pulmonary metastasectomy for CRC included mostly
patients without liver metastases, or were conducted at a
time when hepatectomy was rarely considered in patients
with extensive liver metastases. The present study was
conducted in order to assess the impact of prior surgery
for liver metastases on the outcome of CRC patients who
subsequently underwent pulmonary metastasectomy.
Methods
We performed a retrospective analysis of all CRC patients
who underwent thoracotomy for lung metastases with a
curative intent in our institution since 1996. Lung surgery
was performed in the Thoracic Surgery Unit and both
resections of primary tumor and liver metastases were
performed in the Visceral Surgery Unit of Geneva Uni-
versity Hospital. We included all patients with a histo-
pathological diagnosis of colorectal adenocarcinoma
metastatic to the lung, whether or not they underwent
prior liver surgery. The following parameters were
recorded and considered for statistical analysis: 1)
patients' characteristics; age, gender: 2) primary tumor
characteristics; TNM stage; location (colon or rectum);
preoperative radiation therapy; adjuvant chemo-and/or
chemotherapy: 3) characteristics of liver metastases when
present; number of metastases and location (uni- versus
bilobar); size of largest metastases: adjuvant chemother-
apy; and type of surgery (metastasectomy versus segmen-
tectomy versus right/left hepatectomy; 4) characteristics
of lung metastases: number and size of the largest metas-
tases; type of surgery performed (wedge versus lobec-
tomy versus pneumonectomy); presence of involved
mediastinal lymph nodes; adjuvant chemotherapy; dis-
ease-free interval between primary tumor resection and
development of liver/lung metastases; and location of
lung metastases (uni-versus bilateral). The study was
conducted in accordance with institutional guidelines of
the Ethics Committee for Clinical Research of Geneva
University Hospital.
Eligibility for surgical resection of lung metastases from
CRC was based upon four criteria: 1) control of primary
tumour considered as achieved; 2) absence of extratho-
racic lesions at the time of lung surgery; 3) possibility to
perform a complete resection (R0) of pulmonary metas-
tases; and 4) adequate pulmonary reserve to tolerate the
planned resection, in accordance with classic oncologic
criteria for pulmonary metastasectomy. Follow-up was
performed in the Surgical Oncology Unit, with repeated
clinical examination and thoracoabdominal CT scan
imaging once a year for 5 years to detect local or systemic
tumor recurrence. In addition all patients underwent
colonoscopy surveillance at 1, 3 and 5 years post colec-
tomy.
Statistical analysis
Survival was assessed from the time of thoracotomy to
the time of last follow-up, and statistical analysis was per-
formed using SPSS® software version 17.0 (SPSS, Chicago,
Illinois, USA). Continuous variables were collapsed into
clinically meaningful categories and compared using chi-
square2 tests. Logistic regression was used to identify
variables associated with either tumor recurrence or
death. We considered for the multivariate model all vari-
ables with univariate p-values < 0.20, and retained in the
final model all variables with an adjusted p-value < 0.1.
Survival curves were calculated according to the Kaplan-
Meier method and difference between groups were ana-
lyzed with log-rank test. All tests were two-sided and a p
value < .05 was considered statistically significant.
Results
Between February 1996 and July 2009, forty patients
(median age 63.5 [range 33-82] years) underwent resec-
tion of pulmonary metastases from CRC. Median follow-
up was 33 (range 4-139) months. Twenty-four (60%)
patients did not have previous liver metastases before
undergoing lung surgery. Sixteen patients underwent
resection of liver metastases with a curative intent.
Median disease-free interval between liver surgery and
the development of lung metastases was 17 (range 0-60)
months. Median disease-free interval between primary
colorectal tumor and development of lung metastases
was 32.5 (range 0-82) months. 27 (67%) patients pre-
sented with a single lung metastasis, and 24 (60%) of lung
metastases were < 3 cm in size. Prethoracotomy CEA
serum level was missing in 22 patients and was elevated
in 11 of the remaining 18 patients. This parameter was
therefore not considered for inclusion in statistical analy-
sis. The clinical and pathological characteristics of these
40 patients and their tumors are summarized in Table 1.
There were no postoperative deaths. For the whole
group, 3- and 5-year overall survival rates after thoraco-
tomy were 70.1 and 43.4%, respectively (Figure 1). In uni-
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lung metastases in the primary tumor (M1/stage IV) was
associated with a high risk for tumor recurrence after
thoracotomy (HR = 3.1; 95% Confidence Interval 1.2-7.8,
p = 0.01) (Table 2). In multivariate analysis, two parame-
ters were correlated with tumor recurrence after thoraco-
tomy; 1) a history of previously resected liver metastases
(HR = 3.8, 95%CI 1.4-9.8); and 2) lung surgery other than
wedge resection (HR = 3.0, 95%CI 1.1-7.8). Prior surgery
for liver metastases was also correlated with an increased
risk of death (HR = 5.1, 95% CI 1.1-24.8, p = 0.04) (Table
3). Median survival after thoracotomy was 87 (range 34-
139) months in the group of patients without liver sur-
gery versus 40 (range 28-51) months in patients who
underwent prior hepatectomy for liver metastases (log-
rank test, p = 0.09). 5-year overall survival rate was 53.8%
in the group of patients with isolated lung metastases ver-
sus 29.2% in the group of patients who had undergone
prior liver metastasectomy (Figure 2).
Discussion
Our series differs from most published reports focusing
on pulmonary metastasectomy, because of the high (40%)
percentage of patients who underwent surgery for liver
metastases prior to thoracotomy. With a median follow-
up of 33.5 and 64 months after thoracotomy and colec-
tomy, respectively, 17 (42.5%) patients are alive and dis-
ease-free, with an overall 5-year survival rate of 43%. The
main parameter associated with both tumor recurrence
(HR = 3.8) and death (HR = 5.1) after thoracotomy is a
history of resected liver metastases. Median survival after
pulmonary metastasectomy was twice longer in CRC
patients without previous liver surgery (87 versus 40
months).
With recent advances in surgical technique as well as
adjuvant chemotherapy, many CRC patients treated with
a curative intent for liver metastases have a prolonged
survival; in specialized centres (and in selected patients),
5-year overall survival rate after hepatectomy for CRC
liver metastases exceeds 50% [21]. Unfortunately, some of
them will eventually develop extra-hepatic tumor recur-
rence, usually in the lung and may be candidates to addi-
tional pulmonary metastasectomy; most clinicians would
concur that R0 resection of pulmonary metastases may
improve survival in this subset of patients [22]. Whether
these patients have identical survival benefit in compari-
son with those patients who developed isolated lung
metastases remains controversial [23]; the data presented
herein, however, clearly indicates that prior surgery for
liver metastases is associated with a higher risk for tumor
recurrence and death after pulmonary metastasectomy.
These results appear hardly surprising (patients with
both liver and lung metastases are more likely to have sys-
temic disease), yet the correlation between prior liver
metastasectomy and poor survival in patients undergoing
pulmonary metastasectomy had not been reported so far.
Riquet et al. reported a series of 127 patients who
underwent pulmonary metastasectomy; twenty-nine
(23%) of them had undergone previous liver surgery for
liver metastases. Overall 5-year survival was similar to
ours (41%), but there was a trend towards better survival
in patients who had undergone previous resection of liver
metastases [24]. In addition, five recent series (800
patients in total) have failed to identify prior liver metas-
tases as a risk factor for poor outcome after lung metasta-
sectomy in CRC patients [8,16,19,20,25]. In the largest
series of pulmonary metastasectomy for CRC, the pres-
ence of extrathoracic disease was an independent predic-
tive factor for poor survival, but it was unclear whether
these patients had prior liver surgery or not [26].
Table 1: Clinical and Pathological characteristics of 40 crc 
patients who underwent lung metastasectomy
Gender (F/M) 13/27
Age (median, range) years 63.5 (33-82)

















< 3 cm 24
> 3 cm 16
Type of lung resection
Wedge resection or segmentectomy 32
Lobectomy 7
Pneumonectomy 1
Disease-free interval median (range) 
months
32.5 (0-82)
Colectomy to lung metastases
Disease-free interval median (range) 
months
17 (0-60)
Hepatectomy to lung metastases
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small number of patients and the fact that perioperative
management of patients was not uniform in terms of
(neo) adjuvant chemotherapy. There is certainly a possi-
bility for introducing selecting bias in non-randomized
studies. The strength of our series is related to the high
percentage of patients who underwent prior liver surgery,
allowing for sound comparison of survival between
groups with adequate statistical power despite limited
number of events. Finally, this series reflects the outcome
of a relatively homogenous population of patients who
were treated according to similar clinical guidelines, by a
small group of surgeons over a relatively short period of
time.
Table 2: Relative hazards of recurrence or death in patients with pulmonary metastases secondary to colo-rectal cancer 
(univariate analysis in cox proportional hazards model, time since operation for lung metastasis)
Recurrence Death
Gender (F versus M) 2.1 (0.8 - 5.1) 0.12 1.7 (0.6 - 4.4) 0.30
Age (per 10 years) 0.84 (0.52 - 1.34) 0.46 1.05 (0.61 - 1.79) 0.86
Primary Tumor T stage 0.34 0.60
1-2 1.0 1.0
3 4.0 (0.5 - 30.5) 2.8 (0.4 - 21.7)
4 2.6 (0.3 - 23.3) 3.0 (0.3 - 27.1)
Tumor 3-4 (vs. 1-2) 3.6 (0.5 - 26.8) 0.22 2.8 (0.4 - 21.6) 0.32
Primary Tumor N stage 0.23 0.42
0 1.0 1.0
1 2.3 (0.8 - 6.9) 1.7 (0.5 - 5.6)
2 2.7 (0.8 - 9.3) 2.2 (0.6- 7.8)
Node 1-2 (versus 0) 2.4 (0.9 - 6.7) 0.09 1.9 (0.7 - 5.5) 0.22
Primary tumors M stage 3.2 (1.1 - 8.9) 0.03 1.4 (0.5 - 4.5) 0.53
M1 (versus M0)
Stage 3-4 (versus 1-2) 2.4 (0.9 - 6.7) 0.09 1.8 (0.6 - 5.1) 0.28
Liver metastasis 3.1 (1.2 - 7.8) 0.01 2.3 (0.8 - 6.2) 0.10
Time primary to lung (per year) 0.9 (0.6 - 1.2) 0.51 1.0 (0.8 - 1.4) 0.87
Time primary to first metastasis (per year) 0.71 (0.49 - 1.02) 0.06 0.9 (0.6 - 1.2) 0.45
Multiple versus single lung metastasis 1.2 (0.5 - 3.3) 0.67 1.2 (0.9 - 1.7) 0.17
Size lung metastasis >20 mm 1.8 (0.7 - 4.8) 0.21 1.2 (0.4 - 3.2) 0.76
Neo-adjuvant treatment for lung metastasis 2.8 (0.6 - 13.0) 0.20 3.4 (0.9 - 12.4) 0.06
Adjuvant treatment for lung metastasis 0.5 (0.1 - 3.9) 0.52 1.1 (0.3 - 4.9) 0.89
Lung operation other than wedge (versus 
wedge)
2.3 (0.9 - 5.9) 0.06 1.8 (0.7 - 5.0) 0.23
Table 3: Multivariate analysis of risk factors for tumor recurrence and death
Recurrence Death
Node 1-2 (versus 0) 1.7 (0.6 - 5.0) 0.34 1.5 (0.5 - 4.8) 0.48
Time primary to first metastasis (per year) 0.83 (0.48 - 1.44) 0.51 1.3 (0.8 - 2.1) 0.35
Liver metastasis 2.7 (0.7 - 10.0) 0.14 5.1 (1.1 - 24.8) 0.04
Size lung metastasis >20 mm 2.1 (0.6 - 6.6) 0.23 0.9 (0.3 - 2.7) 0.86
Multiple versus single lung metastasis 1.4 (0.4 - 4.6) 0.58 3.4 (0.9 - 12.9) 0.07
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A minority of CRC patients (10%) with lung metastases
are candidates for surgery with curative intent. In this
selected category of patients, a subset has previously
developed liver metastases, which were resected with a
curative intent. The question of whether to perform pul-
monary metastasectomy in this situation will get more
complex with advances in chemotherapy. A history of
previous liver metastases is certainly not a contra-indica-
tion for pulmonary metastasectomy, but the data pre-
sented here indicates that these patients have a higher
risk of tumor recurrence and a decreased survival in
comparison with patients who underwent surgery for
lung-only CRC metastases. These results are clinically
relevant, since the incidence of isolated lung metastases
without associated liver metastases is low (<10%); a his-
tory of previously resected liver metastases should be
considered a poor prognostic factor in the small subset of
CRC patients candidates for pulmonary metastasectomy.
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